Evidence map›Paper›PMID 36158885›Full record

ArticleBioMed research international2022

Multiomics Integrative Analysis Identifying

Yongmei Dai, Wenhan Chen, Junpeng Huang, Lijing Zheng, Qing Lin, Tongjian Cui, Chen Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Multiomics Integrative Analysis IdentifyingBioMed research international · 2022
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongmei DaiDepartment of Oncology, Shengli Clinical Medical College of Fujian Medical University & Fujian Provincial Hospital, Fujian 350001, China.ORCID https://orcid.org/0000-0001-8473-4893
Wenhan ChenThe Second Clinical Medical College of Fujian Medical University, Fujian 362000, China.
Junpeng HuangDepartment of Oncology, Shengli Clinical Medical College of Fujian Medical University & Fujian Provincial Hospital, Fujian 350001, China.
Lijing ZhengDepartment of Oncology, Shengli Clinical Medical College of Fujian Medical University & Fujian Provincial Hospital, Fujian 350001, China.
Qing LinDepartment of Oncology, Shengli Clinical Medical College of Fujian Medical University & Fujian Provincial Hospital, Fujian 350001, China.
Tongjian CuiDepartment of Oncology, Shengli Clinical Medical College of Fujian Medical University & Fujian Provincial Hospital, Fujian 350001, China.ORCID https://orcid.org/0000-0002-0866-7649
Chen HuangShengli Clinical Medical College of Fujian Medical University & Fujian Provincial Hospital, Fujian 350001, China.ORCID https://orcid.org/0000-0002-8787-4223

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Biomarker research in head and neck squamous cell carcinoma (HNSCC) is constantly revealing promising findings. An enhancer of polycomb homolog 1 ( Methods: The Kaplan-Meier plotter was used to evaluate the prognostic significance of Results: According to the clinical data, high Conclusion: High

Indexed as

Head and Neck NeoplasmsMicroRNAsPapillomavirus InfectionsChromosomal Proteins, Non-HistoneHumansPrognosisRepressor ProteinsSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentChromosomal Proteins, Non-HistoneEPC1 protein, humanMicroRNAsRepressor Proteins

Identifiers

PMID36158885
PMCPMC9507713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.